Concept
Melanoma Progress
Cancer in 2026: How Immunotherapy Is Reshaping the Odds - Cancer Research Institute / Immunotherapy Is Helping Rewrite Survival Curves
"“When we look at metastatic melanoma survival improving from 16% to 35% in just 25 years, we’re witnessing the direct impact of immune checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 therapies. These are the breakthroughs that the Cancer Research Institute has championed for decades — supporting the fundamental science that made immunotherapies a reality.”– Antoni Ribas, MD, PhD, Professor at UCLA and CRI Scientific Advisory Council member"
Related Ideas
- Immunotherapy ReachCancer in 2026: How Immunotherapy Is Reshaping the Odds - Cancer Research Institute · What the Report Means for Immunotherapy
- Research ProgressCancer in 2026: How Immunotherapy Is Reshaping the Odds - Cancer Research Institute · The Road Ahead
- Cancer ProgressCancer in 2026: How Immunotherapy Is Reshaping the Odds - Cancer Research Institute · Progress Is Real, But Uneven
- Cancer ImmunotherapyCancer in 2026: How Immunotherapy Is Reshaping the Odds - Cancer Research Institute · Introducing CRI’s 2025 Cancer Immunotherapy Insights + Impact Report: Evolution of Immunotherapy, FDA Approvals & Next-Generation Treatment Trends
- Research FundingCancer in 2026: How Immunotherapy Is Reshaping the Odds - Cancer Research Institute · What the Report Means for Immunotherapy
- Immunotherapy InsightsCancer in 2026: How Immunotherapy Is Reshaping the Odds - Cancer Research Institute · Immunotherapy vs. Chemotherapy: What’s the Difference?
- CRI SupportCancer in 2026: How Immunotherapy Is Reshaping the Odds - Cancer Research Institute · Join CRI in Shaping the Future of Immunotherapy
- Equal AccessCancer in 2026: How Immunotherapy Is Reshaping the Odds - Cancer Research Institute · The Road Ahead